302 related articles for article (PubMed ID: 18608100)
21. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.
Messi ML; Clark HM; Prevette DM; Oppenheim RW; Delbono O
Exp Neurol; 2007 Sep; 207(1):52-63. PubMed ID: 17597610
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.
Lange DJ; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Lai EC; Murphy MF; Natter HM; Norris FH; Rudnicki S
Neurology; 1996 Oct; 47(4 Suppl 2):S93-4; discussion S94-5. PubMed ID: 8858058
[No Abstract] [Full Text] [Related]
23. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies.
Wei Y; Zhong S; Yang H; Wang X; Lv B; Bian Y; Pei Y; Xu C; Zhao Q; Wu Y; Luo D; Wang F; Sun H; Chen Y
Eur J Med Chem; 2024 Jun; 272():116496. PubMed ID: 38759454
[TBL] [Abstract][Full Text] [Related]
24. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients.
Doré S; Krieger C; Kar S; Quirion R
Brain Res Mol Brain Res; 1996 Sep; 41(1-2):128-33. PubMed ID: 8883943
[TBL] [Abstract][Full Text] [Related]
25. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
26. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.
Gribkoff VK; Bozik ME
CNS Neurosci Ther; 2008; 14(3):215-26. PubMed ID: 18801114
[TBL] [Abstract][Full Text] [Related]
27. The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector.
Wen D; Cui C; Duan W; Wang W; Wang Y; Liu Y; Li Z; Li C
Brain Res Bull; 2019 Jan; 144():1-13. PubMed ID: 30414993
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic trials in ALS.
Bradley W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
[No Abstract] [Full Text] [Related]
29. Therapeutic advances in amyotrophic lateral sclerosis.
Louvel E; Hugon J; Doble A
Trends Pharmacol Sci; 1997 Jun; 18(6):196-203. PubMed ID: 9226998
[TBL] [Abstract][Full Text] [Related]
30. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.
Lepore AC; Haenggeli C; Gasmi M; Bishop KM; Bartus RT; Maragakis NJ; Rothstein JD
Brain Res; 2007 Dec; 1185():256-65. PubMed ID: 17963733
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ; Windbank AJ; Mandrekar JN; Bamlet WR; Appel SH; Armon C; Barkhaus PE; Bosch P; Boylan K; David WS; Feldman E; Glass J; Gutmann L; Katz J; King W; Luciano CA; McCluskey LF; Nash S; Newman DS; Pascuzzi RM; Pioro E; Sams LJ; Scelsa S; Simpson EP; Subramony SH; Tiryaki E; Thornton CA
Neurology; 2008 Nov; 71(22):1770-5. PubMed ID: 19029516
[TBL] [Abstract][Full Text] [Related]
32. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity.
Dodge JC; Haidet AM; Yang W; Passini MA; Hester M; Clarke J; Roskelley EM; Treleaven CM; Rizo L; Martin H; Kim SH; Kaspar R; Taksir TV; Griffiths DA; Cheng SH; Shihabuddin LS; Kaspar BK
Mol Ther; 2008 Jun; 16(6):1056-64. PubMed ID: 18388910
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing a patient's decision regarding riluzole: an early experience.
Rudnicki SA
J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
[TBL] [Abstract][Full Text] [Related]
35. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
Goyal NA; Mozaffar T
Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
[TBL] [Abstract][Full Text] [Related]
36. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.
Shandilya A; Mehan S
Neurol Sci; 2021 Aug; 42(8):3145-3166. PubMed ID: 34018075
[TBL] [Abstract][Full Text] [Related]
38. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.
Morren JA; Galvez-Jimenez N
Expert Opin Investig Drugs; 2012 Mar; 21(3):297-320. PubMed ID: 22303913
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.
Jeon GS; Im W; Shim YM; Lee M; Kim MJ; Hong YH; Seong SY; Kim M; Sung JJ
Neurochem Res; 2016 Apr; 41(4):913-23. PubMed ID: 26646002
[TBL] [Abstract][Full Text] [Related]
40. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis.
Torres-Aleman I; Barrios V; Berciano J
Neurology; 1998 Mar; 50(3):772-6. PubMed ID: 9521273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
